Viking Therapeutics (VKTX) Income towards Parent Company (2014 - 2026)

Viking Therapeutics has disclosed Income towards Parent Company across 13 years of filings, most recently posting -$158.3 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$158.3 million, down 247.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$472.4 million (down 268.29% YoY), and the FY2025 annual result was -$359.6 million, down 227.0% from the prior year.
• Income towards Parent Company came in at -$158.3 million for Q1 2026 at Viking Therapeutics, roughly flat from -$157.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$15.7 million in Q3 2022 to a low of -$158.3 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$24.6 million (2023), against an average of -$46.0 million.
• Across the five-year window, Income towards Parent Company declined 10.44% in 2023 and tumbled 345.56% in 2025, its largest moves.
• Viking Therapeutics' Income towards Parent Company stood at -$19.6 million in 2022, then fell by 25.72% to -$24.6 million in 2023, then sank by 44.0% to -$35.4 million in 2024, then tumbled by 345.56% to -$157.7 million in 2025, then decreased by 0.39% to -$158.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$158.3 million (Q1 2026), -$157.7 million (Q4 2025), and -$90.8 million (Q3 2025), per Business Quant data.